Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Repeated treatments of drooling with botulinum toxin B in neurology

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Prevention after stroke: A quality assurance study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Does continuous electroencephalography influence therapeutic decisions in neurocritical care?

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Transcranial low-frequency pulsating electromagnetic fields (T-PEMF) as post-concussion syndrome treatment

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Effect and efficacy of lifestyle interventions as secondary prevention

    Research output: Contribution to journalReviewResearchpeer-review

  5. Prevalence and risk of occult cancer in stroke

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Cerebrospinal fluid and plasma distribution of anti-α-synuclein IgMs and IgGs in multiple system atrophy and Parkinson's disease

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. TDP-43-specific Autoantibody Decline in Patients With Amyotrophic Lateral Sclerosis

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Exploring Movement Impairments in Patients With Parkinson's Disease Using the Microsoft Kinect Sensor: A Feasibility Study

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Author Correction: Assessment of brain reference genes for RT-qPCR studies in neurodegenerative diseases

    Research output: Contribution to journalComment/debateResearchpeer-review

View graph of relations

OBJECTIVES: To investigate efficacy, saliva flow, and composition in repeated BoNT-B treatments of drooling.

MATERIALS AND METHODS: Seventeen neurological patients (median 66 years), referred for treatment of drooling participated in this observational study. Median total doses of 4000 units botulinum toxin type B (BoNT-B, Neurobloc(®) ) were injected with at least 3 months intervals into parotid and submandibular glands using ultrasound guidance. Measures of drooling and saliva collection for analysis were obtained before treatment, and 6, 12, and eventually 18 weeks after.

RESULTS: Number of treatment series in each patient was 1-7. Compared to baseline, saliva flow rate and drooling were reduced 30-70% 6 weeks after treatment in the first series, while sodium, chloride, and total protein increased 20-80% (t-tests; P < 0.05). After 12 weeks, drooling was still significantly reduced, saliva flow tended to be, and saliva composition was back to baseline. Frequent side effects were viscous saliva and dry mouth. Due to fading effect in eight patients, individual decisions were taken to change from BoNT-B to BoNT-A. Similarly, the outcome was significantly reduced over time in six patients completing five subsequent BoNT-B treatment series (ANOVA; P < 0.05).

CONCLUSION: In the first series, BoNT-B treatment resulted in marked reduction of drooling and saliva flow rate with some relapse after 12 weeks. The viscous saliva was ascribed to increased total protein content and compensatory mechanisms related to ß-adrenergic receptor-specific actions. With patients needing long-term treatment, it should be noted that the efficacy of repeated BoNT-B may fade with time.

Original languageEnglish
JournalActa Neurologica Scandinavica
Volume131
Issue number1
Pages (from-to)51-57
ISSN0001-6314
DOIs
Publication statusPublished - 2015

Bibliographical note

Acta Neurologica Scandinavica
Volume 131, Issue 1, pages 51–57, January 2015

ID: 44767850